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Worldwide, ≈10% of women have high blood pressure (BP) during pregnancy.1 Hypertensive disorders in preg-
nancy (HDP), including preeclampsia, are one of the common-
est causes of maternal mortality2,3 and are a leading cause of 
direct maternal deaths in the United Kingdom.4,5
Hypertension is commonly defined as systolic BP of ≥140 
mm Hg or diastolic BP ≥90 mm Hg. If hypertension presents 
after 20 weeks gestation, it is known as gestational hypertension, 
and when combined with the presence of maternal organ dys-
function, uteroplacental dysfunction, or significant proteinuria 
(>300 mg proteinuria/24 hours or >30 mg/mmol creatinine 
[protein-creatinine ratio]), it is known as preeclampsia.6–11 
Preeclampsia complicates 2% to 8% of all pregnancies and up 
to 25% of pregnancies in women with chronic hypertension.12
Current guidelines identify risk factors for preeclampsia 
based on medical and family histories.6,13 The UK guidelines 
Received February 13, 2018; first decision February 26, 2018; revision accepted June 22, 2018.
From the Nuffield Department of Primary Care Health Sciences (K.L.T., C.B., R.S., C.H., C.C., K.S.T., R.J.M.) and Bodleian Health Care Libraries 
(N.R.), University of Oxford, United Kingdom; Institute of Applied Health Research, University of Birmingham, United Kingdom (J.H.); Obstetric, 
Medicine Division, Department of Obstetrics and Gynecology, CHU Ste-Justine, Montreal, Quebec, Canada (É.R.); Omnicare Women’s Health Centre, 
Auckland, New Zealand (C.L.); Guy’s and St Thomas’ NHS Foundation Trust, Department of Women’s Health, St Thomas’ Hospital, London, United 
Kingdom (M.C.); Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand (R.S.T., 
J.W.); Auckland City Hospital, New Zealand (R.A.N.); Fetal Medicine Unit, St George’s University Hospitals NHS Foundation Trust, London, United 
Kingdom (A.K.); Molecular and Clinical Sciences Research Institute, St George’s University of London, United Kingdom (A.K.); Vascular Biology 
Research Centre, Molecular and Clinical Sciences Research Institute, St George’s University of London, United Kingdom (A.K.); Department of Obstetrics 
and Gynecology, The George Washington University School of Medicine and Health Sciences, DC (K.M.); Royal Victoria Infirmary, Newcastle upon Tyne, 
United Kingdom (J.W.); Department of Obstetrics and Gynecology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand (J.W.), 
Department of Renal Medicine; St. George Hospital and University of NSW, Sydney, Australia (M.B.); and Oxford University Hospitals NHS Foundation 
Trust, Women’s Centre, John Radcliffe Hospital, Oxford, United Kingdom (L.M.).
The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.118.10917.
Correspondence to Richard J. McManus, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Woodstock Rd, 
University of Oxford, OX2 6GG, United Kingdom. Email richard.mcmanus@phc.ox.ac.uk
Abstract—Hypertensive disorders during pregnancy result in substantial maternal morbidity and are a leading cause of 
maternal deaths worldwide. Self-monitoring of blood pressure (BP) might improve the detection and management 
of hypertensive disorders of pregnancy, but few data are available, including regarding appropriate thresholds. This 
systematic review and individual patient data analysis aimed to assess the current evidence on differences between clinic 
and self-monitored BP through pregnancy. MEDLINE and 10 other electronic databases were searched for articles 
published up to and including July 2016 using a strategy designed to capture all the literature on self-monitoring of BP 
during pregnancy. Investigators of included studies were contacted requesting individual patient data: self-monitored 
and clinic BP and demographic data. Twenty-one studies that utilized self-monitoring of BP during pregnancy were 
identified. Individual patient data from self-monitored and clinic readings were available from 7 plus 1 unpublished 
articles (8 studies; n=758) and 2 further studies published summary data. Analysis revealed a mean self-monitoring clinic 
difference of ≤1.2 mm Hg systolic BP throughout pregnancy although there was significant heterogeneity (difference 
in means, I2 >80% throughout pregnancy). Although the overall population difference was small, levels of white coat 
hypertension were high, particularly toward the end of pregnancy. The available literature includes no evidence of a 
systematic difference between self and clinic readings, suggesting that appropriate treatment and diagnostic thresholds for 
self-monitoring during pregnancy would be equivalent to standard clinic thresholds.  (Hypertension. 2018;72:686-694. 
DOI: 10.1161/HYPERTENSIONAHA.118.10917.) • Online Data Supplement
Key Words: blood pressure ◼ hypertension ◼ pre-eclampsia ◼ pregnancy ◼ white coat hypertension
How Do Home and Clinic Blood Pressure Readings 
Compare in Pregnancy?
A Systematic Review and Individual Patient Data Meta-Analysis
Katherine L. Tucker, Clare Bankhead, James Hodgkinson, Nia Roberts, Richard Stevens,  
Carl Heneghan, Évelyne Rey, Chern Lo, Manju Chandiramani, Rennae S. Taylor,  
Robyn A. North, Asma Khalil, Kathryn Marko, Jason Waugh, Mark Brown, Carole Crawford,  
Kathryn S. Taylor, Lucy Mackillop, Richard J. McManus
© 2018 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access 
article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any 
medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
Hypertension is available at https://www.ahajournals.org/journal/hyp DOI: 10.1161/HYPERTENSIONAHA.118.10917
Preeclampsia, Pregnancy, and Hypertension
D
ow
nloaded from
 http://ahajournals.org by on September 17, 2018
Tucker et al  Self-Monitoring BP in Pregnancy: An IPD Analysis  687
recommend BP monitoring with increased frequency in those 
at higher risk of preeclampsia.6 Despite this, women still 
develop preeclampsia in the interval between antenatal visits, 
and a significant proportion of subsequent deaths occur after 
HDP, which developed after apparently normal antenatal vis-
its.14 Reliance on intermittent clinic measurements may lead 
to both false-positive (white coat hypertension [WCH]) and 
-negative (masked hypertension) interpretations. Enhanced 
identification of developing hypertension among higher risk 
women could improve outcomes.
Self-monitoring of BP (SMBP), where individuals measure 
their own BP in a home setting, allows multiple measurements 
for several days with little disturbance of lifestyle and is now 
commonplace in adults with hypertension.15–17 Regular SMBP 
might improve detection of hypertension in the pregnant popula-
tion while reducing the time, money, and inconvenience of fre-
quent appointments, without compromising the ability to detect 
and monitor a potentially serious disease. Potential advantages 
of SMBP include more frequent BP monitoring, improved accu-
racy, and increased acceptability to pregnant women.18,19
The importance and potential of self-monitored BP 
measurement has been noted in both a joint statement 
from the American Heart Association, American Society 
of Hypertension, and Preventive Cardiovascular Nurses 
Association and the recent European Society of Hypertension 
guidelines.20 Consequently, in some countries, SMBP during 
pregnancy is becoming common: a Canadian pilot survey found 
>60% of women diagnosed with nonproteinuric hypertension 
in pregnancy were already SMBP.21 A subsequent survey, of 
Canadian obstetricians and primary care physicians, found that 
most used SMBP to check for WCH (where BP is higher in 
clinic than at home) rather than ambulatory BP monitoring.22
Thresholds for SMBP in the hypertensive nonpregnant 
population are generally lower than when using clinic moni-
toring, but the clinic−home difference varies dependent on 
the population,23,24 and general populations have been shown 
to have minimal differences between home and clinic read-
ings.25,26 Recent guidelines from the society of Obstetrician 
and Gynaecologists of Canada suggest a self-monitoring 
threshold of 135/85 mm Hg.27 However, there are limited data 
on SMBP monitoring during pregnancy to guide such recom-
mendations. This study aimed to systematically review the 
available evidence for differences between self-monitored and 
clinic BP during pregnancy and investigate this using individ-
ual patient data (IPD) where available.
Methods
Data Availability
Data were obtained from third parties for this project. Several of the 
participating studies required specific data sharing agreements from 
their host institution. Current agreements are for the purposes of this 
analysis alone, and as such new approval would be required. Requests 
for Data Sharing should be directed to information.guardian@
phc.ox.ac.uk. Such requests will be considered by all data holders 
involved in this collaboration. There were no specific study materials.
Search Strategy for Identification of Studies
The searches were run from database inception to July 2016, using 
a combination of title/abstract keywords and subject headings for 
self-measurement, BP, and pregnancy (Figure S1 in the online-only Data 
Supplement). No date or publication date limits were applied. We searched 
the Cochrane Database of Systematic Reviews, Database of Abstracts 
of Reviews of Effectiveness, Cochrane Central Register of Controlled 
Trials (The Cochrane Library, Wiley), Medline (OvidSP; 1946–present), 
Embase (OvidSP; 1974–present), CINAHL (EbscoHOST; 1980–pres-
ent), PsycINFO (OvidSP; 1967–present), Science Citation Index 
Expanded, Social Sciences Citation Index, Conference Proceedings 
Citation Index-Science & Conference Proceedings Citation Index-
Social Science & Humanities (Web of Knowledge; 1945–present).
Inclusion Criteria
All primary studies of any study design that included SMBP during 
pregnancy in a sample of multiple women were included. Each cor-
responding author was contacted requesting IPD or summary data 
for self-monitored and clinic BP. Studies that provided clinic and 
self-monitored data or published sufficient data to allow comparison 
were included in the analysis. This study was registered on Prospero: 
CRD42016050528.
Data Extraction
Two reviewers (K.T. and J.H.) independently reviewed the titles and 
abstracts of identified articles and, after assessment of the full text of 
potentially relevant papers, extracted data (Figure S2). Data extrac-
tion included a methodological quality assessment adapted from the 
Quality Assessment of Diagnostic Accuracy Studies checklist28—clear 
selection criteria for participants, response rate, validation of sphyg-
momanometer, validation of self-monitored readings, and blinding 
of those performing clinic measurements. Data extractions were per-
formed in duplicate and disagreements resolved by consensus.
Individual Patient Data
Authors from all eligible studies were approached to provide anony-
mized IPD. The data were considered at 4 time periods (5–14, 15–22, 
23–32, and 33–42 weeks’ gestation), and these were chosen to enable 
the inclusion and analysis of relevant comparative data from included 
studies throughout pregnancy. A trimester-based comparison would 
have resulted in loss of data or inappropriate comparisons.
Data Analysis and Statistical Methods
The absolute differences in BP between clinic and self-measurements 
were calculated (means and SDs) across all studies and in subgroups 
according to gestational stage. These differences were calculated 
using the nearest (closest in time, within 3 days either side) clinic and 
self-monitored readings for each woman in each comparison period, 
including only one comparison per women per stage (5–14, 15–22, 
23–32, and 33–42 weeks) to avoid bias toward women who com-
pleted more readings than others.
Meta-analysis was undertaken in Stata13 (StataCorp, LP) to create 
forest plots, and the I2 statistic was used to estimate statistical hetero-
geneity for each outcome. IPD data were used to calculate the means 
of differences. A subgroup analysis of normotensive and hypertensive 
participants (based on clinic BP ≥140/90) was completed to examine 
differences between the groups. To compare with aggregate data, the 
difference in means was also calculated. Where substantial heteroge-
neity was detected, the direction of effect was assessed, and potential 
reasons for heterogeneity were considered. A random-effects analysis 
was used, and differences between self-monitored and clinic readings 
were assessed using scatter and Bland-Altman plots.
Definitions
There was no evidence before this work to guide the definitions of 
hypertension on the basis of home readings. In general unselected 
populations, there is little difference between home and clinic read-
ings.25,26 The results from the review, which included mixed popula-
tions of both normotensive and hypertensive women, suggested little 
overall difference between home and clinic readings. Current UK and 
international guidelines use a clinic threshold of 140/90 mm Hg for 
diagnosing hypertension during pregnancy. For the purposes of this 
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work, true hypertension was considered present when self-monitored 
and clinic readings both had systolic BP ≥140 and diastolic BP ≥90 
mm Hg in the comparison period. Masked hypertension was defined 
as normotensive clinic BP <140/90 mm Hg with self-monitored 
readings of systolic BP ≥140 or diastolic BP ≥90 mm Hg. Finally, 
WCH was defined as clinic systolic BP ≥140 mm Hg and diastolic 
BP ≥90 mm Hg with normotensive self-monitored readings (<140/90 
mm Hg). Recognizing that home monitoring thresholds for hyperten-
sion suggested for the nonpregnant hypertensive population are lower 
(135/85 mm Hg), a sensitivity analysis was performed using a home 
threshold for hypertension of 135/85 mm Hg.
Results
Findings From the Systematic Review
From 2654 journal articles identified, 121 were assessed in 
full. Twenty-one articles included SMBP during pregnancy 
in a sample of multiple women. Corresponding authors were 
contacted requesting IPD or summary data for self-monitored 
and clinic BP: there was no reply from 4 and a further 10 were 
unable to provide IPD, leaving 7 studies (6 authors) where 
investigators provided BP data from both self-monitoring and 
clinic BP during pregnancy (n=596; Figure 1).29–34 One further 
study undertaken by our group and not published in full at 
the time was included (n=162; total 758).35 Of the 10 studies 
unable to provide data, 2 had published summary data of self-
monitored-clinic comparison (Table 1).36,37
Characteristics of Studies Included in the IPD 
Analysis
Included studies were performed between 2002 and 2017 on 
a range of populations, including women with a healthy preg-
nancy,31,38 women with suspected hypertension,29,30 and those 
with known gestational hypertension or preeclampsia.31,32,34 
Considerable variation was seen in both monitoring schedules 
and the gestation period when the readings were taken. Only 
2 studies used a monitor that had passed validation testing in 
pregnancy (Table 2).34,35
Difference Between Self-Monitored and Clinic 
Readings Though Pregnancy
IPD from the 8 included studies (n=758),29–35,38 contained BP 
readings throughout pregnancy (Figure 2). The overall mean 
differences between home and clinic readings appeared small 
throughout pregnancy (Table 3), with mean of differences 
between 1.5 to 2.2 mm Hg systolic (Figure 2) and 0.7 to 1.5 
mm Hg diastolic BP (Figure S3). However, there was signifi-
cant heterogeneity between studies (I2 >80 at all gestational 
stages for systolic BP), which was only slightly improved by 
removal of single studies.
Subgroup analysis of normotensive and hypertensive 
groups showed that normotensive pregnant women have little 
differences between home and clinic readings with mean dif-
ferences between −0.6 and 1.2 mm Hg systolic (Figures S9 
and S10) and −0.6 and 0.7 mm Hg diastolic. Hypertensive 
women, however, had much larger differences between home 
and clinic (Figures S7 and S8). The heterogeneity remained 
high, and the number of hypertensive participants included at 
the early stages of pregnancy was low.
Differences in means (office and home) were plotted 
for both the IPD data and summary data from other studies 
where possible (Figures S4 and S5).36,37 Reported differences 
in means were higher from studies for which IPD data were 
not available (4.06 mm Hg at 15–22/40 and 2.9 mm Hg at 
23–32/40).36,37
Influence of Absolute BP on Mean Difference 
Between Self-Monitored and Clinic Readings
Bland-Altman and scatter plots show good agreement between 
self-monitored and clinic BP across the range of both systolic 
and diastolic pressures (Figure 3; Figure S6). At later gesta-
tion, the number of readings above the limits of agreement 
were higher than in early pregnancy (Figure 3).
Prevalence of True and WCH by Gestation
As gestation increased, mean clinic BP initially remained 
low, and then began to rise from 33 weeks gestation. Using a 
threshold of ≥140/90 mm Hg for hypertension for both clinic 
and self-monitored BP, the prevalence of true hypertension 
and WCH increased with gestation. At 33 to 42 weeks, the 
prevalence of WCH and true hypertension was similar, indi-
cating women with hypertension on clinic measurements were 
as likely to have normal BP when self-monitoring as they were 
to have true hypertension (Table 3). A sensitivity analysis of a 
self-monitored 135/85 mm Hg threshold is shown in Table S1.
Discussion
This systematic literature review identified 21 studies that 
included SMBP during pregnancy. IPD were available for 
both self-monitored and clinic BP readings from 8 studies 
(758 patients).29–35,38 Comparison of self-monitored and clinic 
readings revealed no clinically relevant difference through-
out pregnancy, with significant heterogeneity between stud-
ies that may be accounted for by the varying populations. 
Figure 1. Flow diagram of the systematic review. Studies included in the 
analysis of clinic and self-monitored blood pressure during pregnancy.
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Interestingly, although overall differences between self-mon-
itored and clinic pressure were small, the prevalence of WCH 
increased reaching 13% toward the end of pregnancy (33–42 
weeks gestation). By this stage, WCH was as prevalent as true 
hypertension.
Strengths and Weaknesses
This study’s strengths include the systematic capture of all 
of the current literature and the inclusion of IPD data from 
8 studies and >750 women. To our knowledge, this is the 
first comparison of self-monitored and office readings using 
data drawn from multiple studies, settings, and countries. 
Weaknesses include that 11 of the 21 studies may have had 
additional data on self-monitored and clinic readings but did 
not publish or provide it.18,39–48 In addition, IPD from the larg-
est study to date were not available.37
All studies had some degree of methodological flaw (or 
lack of clarity), and only 2 studies used a self-monitoring 
device validated in the pregnant population. The validation of 
monitors in pregnancy and preeclampsia is important as preg-
nancy causes changes to the vasculature meaning that many 
generally validated monitors are inaccurate.49 Furthermore, 
the development of preeclampsia leads to significant and 
widespread hemodynamic disturbances, which have been 
shown to affect the accuracy of some BP monitors that are 
accurate in normal pregnancy.50–52 Only 5 monitors have been 
validated for home use in pregnancy.41,53–56
The selection of participants by contributing studies was 
generally clear although details of pregnancy stage were 
sometimes lacking and only 1 study was randomized. Attrition 
reporting was not always clear, and checking of self-monitored 
readings was not reported in any of the studies. Reporting of 
results was generally adequate (Table 2).
Studies were statistically and clinically heterogenous 
reflecting diverse populations (health state, gestation of preg-
nancy) and clinical contexts (date and country of study). Many 
included studies were relatively small and published for a long 
time period (1991–2017), during which time there have been 
advances in BP monitoring technology. Most studies included 
in this review used monitors that have not been validated in 
pregnancy. The monitor used by both Brown et al,29 and Lo et 
al31 subsequently failed validation in the preeclamptic popula-
tion. However, removing these studies from our analysis did 
not remove the observed heterogeneity. It is clear that further 
validation of BP monitors in the pregnant population is needed 
including individuals with preeclampsia and obesity.
A further potential cause of the observed heterogeneity 
could be differences in the populations studied. For exam-
ple, both Lo et al31 and Ishikuro et al37 (Figures S4 and S5) 
observed normotensive healthy pregnant populations, and 
both Brown et al29 and Chandiramani et al30 (Figure 2; Figures 
S3–S5) selected women who had suspected hypertension; 
however, the clinic−self monitored differences in these study 
groups were opposing (Figure 2; Figures S3–S5). It may be 
Table 1. Studies Included in Analysis
Author (Year) Country Population No. of Participants Gestation
IPD
  Brown (2004) Australia Suspected hypertension 66 Average of 23 wk
  Chandiramani (2006) United Kingdom Suspected hypertension 100 Throughout pregnancy
  Lo (2002) New Zealand 1) Healthy pregnancy at booking
2) Women with preeclampsia
101
45*
Throughout pregnancy
>38 wk
  Rey (2007) Canada 1) Hypertensive
2) Normotensive high risk of preeclampsia
100
20
Throughout pregnancy
  Rey (2009) Canada 1) Chronic hypertension
2) Preeclampsia
3) Isolated office hypertension (WCH)
111
41
7*
Third trimester
(28–38 wk gestation)
  Sheehan (2016) United Kingdom Hypertensive pregnancy 93* Throughout pregnancy (12–40 wk)
  Marko (2016) United States first-trimester low risk 100 (50 randomized to 
intervention*)
Through pregnancy
  Tucker (2017) United Kingdom Higher risk pregnancy 201* Throughout pregnancy (12–6 wk 
post-partum)
Summary data only
  Mooney (1991) United Kingdom Any pregnancy 35 30 wk
  Ishikuro (2013) Japan Healthy singleton pregnancy with no history of 
hypertension
575 20 wk till 4 wk post-partum
Table of the 10 studies with BP data for analysis. Eight studies were able to provide IPD and 2 further studies provided summary data. BP indicates blood pressure; 
IPD, individual patient data; and WCH, white coat hypertension.
*Data for both clinic and self-monitored readings were available as follows: Lo et al31 provided data for 102/146 participants, Rey et al32,33, provided data for 
202 participants from combined studies (presented together), Sheehan et al34 provided data for 78 of 93 participants, Marko et al38 provided data from 47 of 50 
participants, and Tucker et al35 provided data from 162 of 201 participants. Data were available from 758 participants (81% of the total participants in the studies 
included in the IPD).
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that the monitor used, schedule of monitoring, or some other 
factor was more influential.
Overall, the data were representative of populations that 
may use home monitoring, either to detect hypertension 
in pregnancy (normotensive pregnancies31,35), differentiate 
between true and WCH (suspected but not confirmed hyper-
tension29,30), or manage hypertension (women with gestational 
hypertension or preeclampsia30–32).
Comparison With the Previous Literature
Clear SMBP thresholds for hypertension in pregnancy have 
not been established in the United Kingdom.23 Canadian 
guidelines recommend a self-monitored threshold of 135/85 
mm Hg although it is unclear on what this is based, presumably 
the nonpregnant population.17,27 A sensitivity analysis using a 
threshold for hypertension of 135/85 mm Hg for home moni-
toring showed a slightly higher level of discordance with diag-
nosis based on clinic readings. However, subgroup analysis of 
women with hypertension (defined by clinic readings) showed 
that this group had a much larger home-office difference, sug-
gesting that this group was selecting for a larger white coat 
effect and therefore lower thresholds may be appropriate.
Previous reports have suggested that the prevalence of 
WCH in pregnancy may be considerable.43,57 In the general 
population, the amount of white coat effect is higher in hyper-
tensive groups compared with normotensive groups.24 This is 
thought to be because the higher average BP is more likely to 
result in variations above threshold and because this popula-
tion may be more anxious about clinic results. This increase in 
white coat effect in hypertensive groups seems also to be true 
in pregnancy as several studies show high prevalence of WCH 
in hypertensive pregnancy.33,37,43,57 Some data suggest that 
women with WCH are at low risk of complications, but oth-
ers that WCH reflects increased variability and hence risk.38 
Further work is required to understand the true prognosis of 
WCH in pregnancy.
Table 2. Methodological Details of the Included Studies
First Author Type of Study
Clear 
Selection 
Criteria
Response 
Rate
Clinic 
Monitor
Same 
Ref 
Standard 
Across 
Sample
Self/Home 
Monitor
Validated 
for Use in 
Pregnancy
Adequate 
Checking 
of Home 
Readings
Regime 
Self-
Monitoring
Time Between 
Comparisons
Blinding 
to Home 
Values
IPD
  Brown et al29 Observational Y NC Routine 
mercury 
sphyg 
(phase V)
Y Omron HEM 
705CP
N N 6× a day Next day NC
  Chandiramani 
et al30
Observational Y NC Microlife 
3BT10
Y Microlife 
3BT10
N N Not clear Not clear NC
  Lo et al31 Observational Y NC Omron 
HEM-
705 and 
Mercury
N Omron
 HEM-705CP
N N 4 readings 
within 24 h
3 readings 24 
h before home 
readings
Y
  Rey et al33 Observational Y NC Aneroid Y Aneroid N N 3×–7× a 
week
Same antenatal 
period
Y
  Rey et al32 Observational Y NC Aneroid Y Aneroid N N 3×–7× a 
week
Average of all 
self-monitored 
readings in 
the week 
preceding.
Y
  Sheehan  
et al34 
Observational Y NC Routine Y Microlife 
WatchBPHome
Y NC Twice a 
day
Closest clinic 
reading*
N
  Marko et al38 Controlled study Y First 100 
women 
in clinic
Routine  NC NC Y NC Closest clinic 
reading*
N
  Tucker et al35 Observational Y NC Routine Y Microlife 
WatchBPHome
Y Monitor 
memory
3 d a week Closest clinic 
reading*
N
Summary data only
  Ishikuro  
et al37
Observational Y 34% Not clear NC Omron 
HEM747IC 
HEM708IC
N NC Every 
morning
Clinic BP every 
4 wk
Y
  Mooney  
et al36
Observational Y NC Not clear NC Not Clear Not known NC Not clear Not clear Y
Table showing the methodological details of the included studies. N indicates no; NC, not clear; and Y, yes.
*The nearest in time was considered the nearest in the 7 days around the first clinic reading (ie, in the 3 days before and 3 days after).
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Perspectives
Current UK guidelines recommend more frequent BP mea-
surements should be considered in those at higher risk of 
preeclampsia.6 It is for these women that SMBP is likely to 
be most effective in terms of diagnosing higher BP in preg-
nancy. SMBP could also be beneficial to identify WCH in 
those presenting with high clinic pressures and to improve 
the monitoring of women with true chronic or gestational 
hypertension.43
If SMBP were to become commonplace in antenatal 
care, reference thresholds for self-monitored readings would 
be needed. Previous studies have examined the normal 
range of out-of-office BP during healthy pregnancy (pre-
dominantly using ambulatory BP monitoring) with varying 
Figure 2. Comparison of clinic and self-monitored systolic blood pressure (BP). Forest plots were constructed to examine the difference in mean BP (clinic–
home) by the type of monitoring and study group. Data were analyzed as continuous variables and presented here in mm Hg, plotted by gestational stage. CI 
indicates confidence interval.
Table 3. Overall Blood Pressure by Gestation Plus Prevalence of True, Masked, and White Coat Hypertension
Gestation, wk 5–14 15–22 23–32 33–42
No. of participants 250 431 519 512
Overall mean clinic BP (SD), mm Hg 117 (14)/72 (11) 118 (14)/72 (10) 120 (15)/74 (12) 126 (16)/80 (12)
Overall mean home BP (SD), mm Hg 118 (14)/73 (10) 117 (13)/72 (9) 120 (13)/74 (10) 125 (13)/79 (9)
Prevalence true normotensive, n (%) 211 (84.4%) 384 (89.1%) 421 (81.1%) 343 (67%)
Prevalence white coat hypertension, n (%) 21 (8.4%) 26 (6.0%) 48 (9.3%) 66 (12.9%)
Prevalence masked hypertension, n (%) 8 (3.2%) 7 (1.6%) 15 (2.9%) 29 (5.7%)
Prevalence true hypertension, n (%) 10 (4%) 14 (3.3) 35 (6.7%) 74 (14.5%)
A threshold of 140/90 mm Hg for both clinic and self-monitored readings was used to determine participants with true normotension (when 
both clinic and self-monitored readings were <140/90 mm Hg) and true hypertension (when both clinic and self-monitored readings were ≥140 
mm Hg systolic or 90 mm Hg diastolic BP). Masked hypertension was defined as clinic BP <140/90 mm Hg and self-monitored readings ≥140 
mm Hg systolic or 90 mm Hg diastolic. Finally, WCH was defined as clinic systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg with normotensive 
self-monitored readings (<140/90 mm Hg). Data were analyzed from the combined IPD set. BP indicates blood pressure; IPD, individual patient 
data; and WCH, white coat hypertension.
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conclusions.42,58 This is the first study to compare self-mon-
itored and office readings across multiple studies. We found 
that self-monitored and clinic readings had little overall differ-
ence, suggesting that a self-monitored threshold equivalent to 
clinic threshold (currently 140/90 mm Hg) would be appropri-
ate during pregnancy for normotensive women. Confirmation 
of this would require a study relating home BP to outcome. 
In addition, although we found little variation in mean dif-
ferences, some women had clinically important differences 
between home and clinic readings, and therefore the prognos-
tic significance of WCH and masked hypertension in preg-
nancy should also be considered. Subgroup analysis revealed 
that hypertensive pregnant women tended to have much larger 
home–office difference than normotensive pregnant women.
The clinical context of home monitoring is an important 
consideration. Whether the self-monitoring was additional to 
standard antenatal clinic visits, or being used as a replacement 
is relevant, as would which group of women are involved; 
those at risk of HDP, or those with HDP (ie, is the monitor-
ing for diagnosis or management of hypertension?). For both 
groups, it would be reasonable to suggest that women with 
home readings of 140/90 mm Hg should be seen in clinic for 
safety. As current guidelines suggest starting medication for 
hypertension at 150/100 mm Hg, additional appointments 
in clinic may not be justified if clinic readings are likely to 
be <140/90 mm Hg. Hypertensive pregnant women defined 
on clinic pressures, however, may require a threshold simi-
lar to the hypertensive population outside pregnancy (135/85 
mm Hg); previous studies have reported a high prevalence of 
WCH, and our subgroup analysis would support this.
Conclusions
This IPD analysis provides the best evidence to date on suit-
able thresholds for the diagnosis of HDP. Although showing 
heterogeneity between studies, overall there seems to be little 
difference between self-monitored and clinic readings. This 
evidence needs to be tempered by the knowledge that most 
monitors used in included studies were not validated and that 
monitoring schedules varied between studies. However, a 
finding of broad equivalence of clinic and home BP is in line 
with general population studies outside of pregnancy, unlike 
those with participants included on the basis of raised BP in 
Figure 3. Agreement between clinic and self-monitored blood pressure (BP) readings during pregnancy. Bland-Altman plots were used to examine the 
influence of mean BP on the clinic−self difference. The mean clinic and self-monitored readings were plotted against clinic−self monitored readings (complete 
cases). At 5 to 14 wk, there was a mean difference of 1.403, 6.8% (17 of 250) readings were outside limits of agreement, and 95% limits of agreement were 
−16.943, 19.750. At 15 to 22 wk, a mean difference of 1.550 was observed, 6.26% (27 of 431) readings were outside limits of agreement, and the 95% 
limits of agreement were −18.576, 21.677. At 23 to 32 wk gestation, there was a mean difference of 1.067, 4.82% (25 of 519) readings were outside limits 
of agreement, and the 95% limits of agreement were −20.736, 22.871. At 33 to 42 wk gestation, there was a mean difference of 1.494, 4.66% (22 of 472) 
readings were outside limits of agreement, and 95% limits of agreement were −19.429, 22.417. Diastolic plots are shown in Figure S6.
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the clinic. In turn, it suggests that home BP thresholds used 
for decision making in an unselected population in pregnancy 
should be equivalent to those currently used in clinic. SMBP, 
therefore, seems to have a role in ruling out WCH in those 
presenting with high clinic pressures. Understanding the true 
place of self-monitored BP in pregnancy will require further 
studies with validated monitors to confirm the equivalence of 
thresholds, including careful linkage to outcomes for women 
and their offspring. In addition, outcome studies are needed 
to better understand the prognosis of both WCH and masked 
hypertension in pregnancy.
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What Is New?
•	This study combined the currently available evidence on clinic and self-
monitored blood pressure during pregnancy to consider thresholds for 
home monitoring.
What Is Relevant?
•	There was little overall difference between self-monitored and clinic 
blood pressure readings, suggesting that appropriate thresholds for self-
monitoring would be equivalent to clinic thresholds.
•	White coat hypertension may be common toward the end of pregnancy, 
and more research is needed to assess the impact of this.
•	More studies using monitors validated in pregnancy are needed.
Summary
Data from >750 pregnant women showed that there was little over 
all difference between self-monitored and clinic blood pressure 
readings. However, there were high levels of white coat hyperten-
sion toward the end of pregnancy.
Novelty and Significance
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